Metacrine Stock (NASDAQ:MTCR)
Previous Close
$NaN
52W Range
$0.49 - $0.49
50D Avg
-
200D Avg
-
Market Cap
$21.69M
Avg Vol (3M)
$52.47K
Beta
-0.74
Div Yield
$0.58
MTCR Company Profile
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
MTCR Performance
Peer Comparison
| Ticker | Company |
|---|---|
| NUVB | Nuvation Bio Inc. |
| MGTA | Dianthus Therapeutics, Inc. |
| MNPR | Monopar Therapeutics Inc. |
| CTMX | CytomX Therapeutics, Inc. |
| SRZN | Surrozen, Inc. |
| VCNX | Vaccinex, Inc. |
| ASMB | Assembly Biosciences, Inc. |
| INDP | Indaptus Therapeutics, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| TARA | Protara Therapeutics, Inc. |
| NLTX | Neurogene Inc. |
| TIL | Instil Bio, Inc. |